The world’s first “RSV vaccine” has been successfully immunized. ‘From mother to child’ Pfizer to file registration this year
Dr. Anan Chongkaewwatana Director of the Research Group on Animal Health and Management Innovation The National Center for Genetic Engineering and Biotechnology (Biotech) has published a Facebook page. Anan Jongkaewwattana About the vaccine field Pfizer can research and manufacture vaccines RSV that will build immunity from mother and child was the world’s first successful message as follows
Good news vaccineRSV Pfizer’s Phase 3 was very effective, able to prevent severe RSV symptoms in infants from postpartum to 3 months of age with 81.8% protection efficiency and Phum will continue to live up to 6 months of age at 69.4%.
Get ready to apply for registration this year.
The vaccine is bivalent, designed for 2 strains of RSV and given to mothers during pregnancy. To pass from mother to child, Pfizer plans to apply for a license to use the vaccine this year: if the FDA gives the green light, it will be considered an RSV vaccine. The first to use the landscape from mother to child.
Read more
